Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease.

Abstract

British Journal of Clinical PharmacologyVolume 9, Issue 1 p. 98-99 Free Access Deprenyl is a selective inhibitor of brain MAO-B in the long-term treatment of Parkinsons's disease. P Reiderer, P ReidererSearch for more papers by this authorGP Reynolds, GP ReynoldsSearch for more papers by this author P Reiderer, P ReidererSearch for more papers by this authorGP Reynolds, GP ReynoldsSearch for more papers by this author First published: January 1980 https://doi.org/10.1111/j.1365-2125.1980.tb04805.xCitations: 14AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References BIRKMAYER, W., RIEDERER, P., YOUDIM, M.B.H. & LINAUER, W. (1975). Potentiation of the anti-akinetic effect after L-Dopa treatment by an inhibitor of MAO-B, deprenil. J. Neural Transmiss., 36, 303– 323. BIRKMAYER, W., RIEDERER, P., AMBROZI, L. & YOUDIM, M.B.H. (1977). Implications of combined treatment with Madopar and deprenil in Parkinson's disease; a long-term study. Lancet, i, 434– 443. ELSWORTH, J.D., GLOVER, V., REYNOLDS, G.P., SANDLER, M., LEES, A.J., PHUAPRADIT, P., SHAW, K.M., STERN, G.M. & KUMAR, P. (1978). Deprenyl administration in man: a selective MAO-B inhibitor without the ‘cheese effect. Psychopharmac., 57, 33– 38. GLOVER, V., SANDLER, M., OWEN, F. & RILEY, G.J. (1977). Dopamine is a monoamine oxidase B substrate in man. Nature, 265, 80– 81. KNOLL, J., (1976). Analysis of the pharmacological effects of selective monoamine oxidase inhibitors. In Monoamine oxidase and its inhibition, ed. G.E.W. Wolstenholme & J. Knight, pp. 135– 162. Amsterdam: Elsevier. LEES, A.J., SHAW, K.M., KOHOUT, L.J., STERN, G.M., ELSWORTH, J.D., SANDLER, M. & YOUDIM, M.B.H. (1977). Deprenyl in Parkinson's disease. Lancet, i, 791– 795. REYNOLDS, G.P., ELSWORTH, J.D., BLAU, K., SANDLER, M., LEES, A.J. & STERN, G.M. (1978). Deprenyl is metabolised to methamphetamine and amphetamine in man. Br. J. clin. Pharmac., 6, 542– 544. RIEDERER, P., YOUDIM, M.B.H., RAUSCH, W.-D., BIRKMAYER, W., JELLINGER, K. & SEEMANN, D. (1978). On the mode of action of L-deprenyl in the human central nervous system. J. Neural Transmiss., 43, 217– 226. STERN, G.M., LEES, A.J. & SANDLER, M. (1978). Recent observations on the clinical pharmacology of deprenyl. J. Neural Transmiss., 43, 245– 251. TIPTON, K. & YOUDIM, M.B.H., (1976). Assay of monoamine oxidase. In Monoamine oxidase and its inhibition, ed G.E.W. Wolstenholme & J. Knight, pp. 393– 403. Amsterdam: Elsevier. Citing Literature Volume9, Issue1January 1980Pages 98-99 ReferencesRelatedInformation